Technical Analysis for ALDX - Aldeyra Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| See historical ALDX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -0.16% | |
| Calm After Storm | Range Contraction | -0.16% | |
| BB Squeeze + Upper Band Touch | Range Contraction | -0.16% | |
| Up 3 Days in a Row | Strength | -0.16% | |
| Upper Bollinger Band Touch | Strength | -0.16% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2019
- Sector: Healthcare
- Industry: Biotechnology
Aldeyra Therapeutics, Inc. (Aldeyra) is a biotechnology company. The Company is focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The Company is developing NS2. NS2 is a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of diseases, which include Sjogren-Larsson Syndrome (SLS), discoid lupus, acute anterior uveitis and ocular rosacea with meibomian gland dysfunction. Aldeyra is also developing aldehyde traps distinct from NS2. As of April 7, 2014, it had evaluated NS2 in a Phase I clinical trial in 48 volunteers.
Medicine Biotechnology Medical Specialties Diseases Organ Systems Autoimmune Diseases Rare Diseases Uveitis Inflammatory Syndromes Systemic Lupus Erythematosus
Medicine Biotechnology Medical Specialties Diseases Organ Systems Autoimmune Diseases Rare Diseases Uveitis Inflammatory Syndromes Systemic Lupus Erythematosus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ALDX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 12.79 |
| 52 Week Low | 4.31 |
| Average Volume | 229,606 |
| 200-Day Moving Average | 6.6956 |
| 50-Day Moving Average | 5.6607 |
| 20-Day Moving Average | 5.875 |
| 10-Day Moving Average | 5.932 |
| Average True Range | 0.3753 |
| ADX | 13.86 |
| +DI | 18.1991 |
| -DI | 16.3914 |
| Chandelier Exit (Long, 3 ATRs ) | 5.1741 |
| Chandelier Exit (Short, 3 ATRs ) | 6.196 |
| Upper Bollinger Band | 6.1652 |
| Lower Bollinger Band | 5.5848 |
| Percent B (%b) | 0.85 |
| BandWidth | 9.879149 |
| MACD Line | 0.1255 |
| MACD Signal Line | 0.1108 |
| MACD Histogram | 0.0147 |
| Fundamentals | Value |
|---|---|
| Market Cap | 37.97 Million |
| Num Shares | 6.25 Million |
| EPS | -1.47 |
| Price-to-Earnings (P/E) Ratio | -4.14 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 4.06 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.49 | ||||
| Resistance 3 (R3) | 6.49 | 6.35 | 6.42 | ||
| Resistance 2 (R2) | 6.35 | 6.25 | 6.35 | 6.39 | |
| Resistance 1 (R1) | 6.22 | 6.19 | 6.29 | 6.22 | 6.37 |
| Pivot Point | 6.08 | 6.08 | 6.12 | 6.08 | 6.08 |
| Support 1 (S1) | 5.95 | 5.98 | 6.02 | 5.95 | 5.79 |
| Support 2 (S2) | 5.81 | 5.92 | 5.81 | 5.77 | |
| Support 3 (S3) | 5.68 | 5.81 | 5.74 | ||
| Support 4 (S4) | 5.68 |
